Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists.

[1]  Harinder Singh,et al.  Suppression of Inflammasome Activation by IRF8 and IRF4 in cDCs Is Critical for T Cell Priming , 2020, Cell reports.

[2]  M. Ennaji,et al.  HPV16 L1 diversity and its potential impact on the vaccination-induced immunity. , 2020, Gene.

[3]  Zachary D Dalebroux,et al.  Outer Membrane Lipid Secretion and the Innate Immune Response to Gram-Negative Bacteria , 2020, Infection and Immunity.

[4]  M. Lehtinen,et al.  Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines , 2020, npj Vaccines.

[5]  M. Lehtinen,et al.  Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines , 2020, npj Vaccines.

[6]  T. Lazzarotto,et al.  HPV-Specific Systemic Antibody Responses and Memory B Cells are Independently Maintained up to 6 Years and in a Vaccine-Specific Manner Following Immunization with Cervarix and Gardasil in Adolescent and Young Adult Women in Vaccination Programs in Italy , 2020, Vaccines.

[7]  S. H. van der Burg,et al.  Long-term HPV-specific immune response after one versus two and three doses of bivalent HPV vaccination in Dutch girls. , 2019, Vaccine.

[8]  S. Reed,et al.  The adjuvant GLA-AF enhances human intradermal vaccine responses , 2018, Science Advances.

[9]  J. Brotherton.  Human papillomavirus vaccination update: Nonavalent vaccine and the two-dose schedule. , 2018, Australian journal of general practice.

[10]  Kelsey A. Gregg,et al.  A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model. , 2018, Vaccine.

[11]  N. Low,et al.  Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis. , 2017, Vaccine.

[12]  Kelsey A. Gregg,et al.  Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery , 2017, mBio.

[13]  R. Roden,et al.  Progress and prospects for L2-based human papillomavirus vaccines , 2016, Expert review of vaccines.

[14]  M. Baseler,et al.  Circulating CXCR5+CD4+ T Follicular-Like Helper Cell and Memory B Cell Responses to Human Papillomavirus Vaccines , 2015, PloS one.

[15]  R. Roden,et al.  Production of Furin‐Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1‐ or L2‐Specific Antibodies , 2015, Current protocols in microbiology.

[16]  Yuanqing Liu,et al.  A Comparative Review of Toll-Like Receptor 4 Expression and Functionality in Different Animal Species , 2014, Front. Immunol..

[17]  P. Andersen,et al.  Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01 , 2014, PloS one.

[18]  P. Rady,et al.  The biology of human papillomaviruses. , 2014, Current problems in dermatology.

[19]  R. Roden,et al.  Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies. , 2014, Virology.

[20]  J. Dillner,et al.  Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses , 2013, The Journal of investigative dermatology.

[21]  D. Lowy,et al.  Phylogenetic Considerations in Designing a Broadly Protective Multimeric L2 Vaccine , 2013, Journal of Virology.

[22]  L. Bruni,et al.  Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease , 2012, Infectious Agents and Cancer.

[23]  R. Coler,et al.  A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. , 2011, Vaccine.

[24]  S. Crotty,et al.  Follicular helper CD4 T cells (TFH). , 2011, Annual review of immunology.

[25]  Magdalini Moutaftsi,et al.  Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant , 2011, PloS one.

[26]  S. Ottonello,et al.  The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies. , 2011, Virology.

[27]  R. Roden,et al.  Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines , 2009, Journal of Virology.

[28]  R. Compans,et al.  Kinetics of Immune Responses to Influenza Virus-Like Particles and Dose-Dependence of Protection with a Single Vaccination , 2009, Journal of Virology.

[29]  I. Bossis,et al.  A Protective and Broadly Cross-Neutralizing Epitope of Human Papillomavirus L2 , 2007, Journal of Virology.

[30]  D. Lowy,et al.  Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. , 2000, Virology.

[31]  S. Harrison,et al.  Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. , 2000, Molecular cell.

[32]  D. Lowy,et al.  In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype , 1996, Journal of virology.